User:Matt Pijoan: Difference between revisions

Jump to navigation Jump to search
No edit summary
(Replaced content with "{{#widget:VisitSchedulerRedux}}")
Tag: Replaced
Line 1: Line 1:
 
{{#widget:VisitSchedulerRedux}}
* Enteropathy-associated [[T-cell lymphoma]] may be classified according to [[World Health Organization]] (WHO) into 2 subtypes:<ref name="biomedcentral">Enteropathy-associated T-cell lymphoma. BioMed Central. http://diagnosticpathology.biomedcentral.com/articles/10.1186/1746-1596-7-172. Accessed on January 28, 2016</ref><ref name="pmid25478355">{{cite journal |vauthors=V G, Kudva R, Amprayil AJ |title=Enteropathy associated T cell lymphoma - a case report of an uncommon extranodal T cell lymphoma |journal=J Clin Diagn Res |volume=8 |issue=10 |pages=FD10–2 |date=October 2014 |pmid=25478355 |pmc=4253173 |doi=10.7860/JCDR/2014/9740.4999 }}</ref>
:* Type I enteropathy-associated T-cell lymphoma
:* Type II enteropathy-associated T-cell lymphoma

Revision as of 18:20, 15 January 2019


Please Note: Clicking the "Delayed infusion" button for Visits 3, 4, and 5 will allow you to select more date options for those visits.

If you have any specific questions about patient scheduling criteria according to the protocol, feel free to contact the AEGIS II Hotline here




Please Note: Visit 1 is not displayed in the Visit Scheduler as Visit 1 is the Screening Visit in which Subject eligibility will be determined. Should the Subject be deemed eligible to participate in AEGIS-II, please randomize the Subject in IRT. This Visit Scheduler is to be used as an aid to calculate the remaining visits once randomization in IRT has occurred. Please enter the same dates from IRT used for First Medical Contact (FMC) and Visit 2 into this Visit Scheduler to calculate the remaining Visits.